

Table 1. COVID-19 Vaccination Guidance by Immunocompromised Population^[1-7]

Group	Suggested timing of 2026-2027 COVID-19 vaccine^{*,**}
Solid organ transplant (SOT)	• At least 2 weeks pre-SOT; or ≥3 months post-SOT
Hematologic malignancy	• Optimal timing includes ≥2 weeks before starting treatment and ≥ 3 months after last infusion ○ For B-cell depletion, consider ≥3-6 months after last infusion • If optimal timing not feasible, administer during treatment (blunted immune response likely)
Hematopoietic cell transplantation (HCT)/Chimeric antigen receptor T-cell therapy (CAR-T)	• Optimal timing includes ≥3 months after transplant or CAR-T treatment ○ For B-cell depletion, consider ≥3-6 months after last infusion • If optimal timing not feasible, administer during treatment (blunted immune response likely)
Solid tumor chemotherapy	• At least 2 weeks before starting therapy; during/after is acceptable
Primary Immuno-deficiency	• Align with IVIG/SCIG or clinic access
Autoimmune immunosuppression	• Optimal timing includes ≥2 weeks before starting treatment and ≥ 3 months after last infusion ○ For B-cell depletion, consider ≥3-6 months after last infusion • If optimal timing not feasible, administer during treatment (blunted immune response likely)
HIV	• Align with preventive routine care

*Defer during acute transplant rejection treatment or severe/acute illness

**Use individualized consideration for early windows based on levels of community virus circulation